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Abstract
Background. Pertussis is a highly communicable, vaccine-preventable respiratory disease. Although the largest number of
reported cases is among young infants, the most rapidly increasing incidence in the USA is in adolescents and young adults.
Importantly, adult family members are the likely major reservoir, infecting susceptible infants before completion of
childhood vaccination. We studied maternal-neonatal paired blood samples for the presence of pertussis-related antibodies
to assess level of immunity and passive transplacental antibody passage.
Methods. Unselected maternal-neonatal cord blood samples were collected from 101 term deliveries in a single urban
uninsured/underinsured hospital setting. Sera were analyzed for anti-pertussis toxin (PT), ﬁlamentous hemagglutinin (FHA)
and pertactin (PRN) IgG antibodies by enzyme-linked immunosorbent assay (ELISA). Antibody titers were calculated using
reference line methodology. Antibody values were log-transformed to establish geometric mean titers (GMT) for analysis.
Student’s t-test, Mann–Whitney, Pearson correlation and chi square were used for statistical comparisons as appropriate.
Results. Mean (SD) maternal age, gestational age and birth weight were 26.8 (6.8) years, 38.9 (1.4) weeks and 3239 (501)
g, respectively. Detectable maternal levels of anti-PT, FHA and PRN were found in 34.7%, 95.0% and 80.2%, respectively.
Maternal GMT (SD) for PT, FHA and PRN were 4.4 (2.6), 26.6 (3.1) and 12.3 (2.9), respectively. There was no signiﬁcant
relationship between PT, FHA or PRN detection or antibody GMT and maternal age. Maternal anti-PT, FHA and PRN
were highly correlated with neonatal cord blood values.
Conclusion. Despite previous childhood immunization, a large number of parous women have low or undetectable
pertussis-related antibody levels, suggesting susceptibility to infection. Even with efﬁcient transplacental passage of these
antibodies, neonates similarly have limited measurable protection as detected by cord blood sampling. These data support
the need for adolescent or adult vaccination against Bordetella pertussis. Healthcare providers and their clients should be aware
of the risk for infant infection via family member transmission.
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Introduction
Pertussis is a highly communicable, vaccine-preven-
table respiratory disease. Although the largest
number of reported cases is among young infants,
the most rapidly increasing incidence in the USA is
in adolescents and young adults [1,2]. Importantly,
adult family members are the likely major reservoir,
infecting susceptible infants before completion of
childhood vaccination. We studied maternal-cord
blood paired samples for the presence of pertussis-
related antibodies to assess level of immunity and
passive transplacental antibody passage.
Methods
Unselected maternal-neonatal cord blood samples
were collected from 101 term deliveries in a single
urban uninsured/underinsured hospital setting.
Although detailed demographic data were not
available, the patient population was more than
80% African-American of USA origin. Samples
were stored at 7208C until analyzed for anti-
pertussis toxin (PT), ﬁlamentous hemagglutinin
(FHA) and pertactin (PRN) IgG antibodies by
enzyme-linked immunosorbent assay (ELISA), as
follows.
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DOI: 10.1080/10647440500068289The antigen of interest was adsorbed onto a
polystyrene microtiter plate. Dilutions of human
sera were added to the PT-, FHA- or PRN-coated
plates and the antibodies speciﬁc for each bound to
the coated antigen. Sera were diluted with phos-
phate-buffered saline containing 0.2% bovine serum
albumin (BSA), and seven serial twofold dilutions
were performed. Each plate included the standard
and two positive controls. Standard and controls
were pools of human sera. The standards used were
internal reference sera calibrated against FDA
control serum lots, deﬁned as containing 200 EU/
ml of IgG antibody (for PT and FHA) and 90 EU/ml
(for PRN). The bound antibodies were detected
using a goat anti-human IgG alkaline phosphatase
labeled antibody followed by p-nitrophenyl phos-
phate substrate. The color developed was directly
proportional to the amount of antibody present in
the serum. Absorbance readings were measured
using a spectrophotometer capable of reading micro-
titer plates. The IgG antibody titers were calculated
relative to the reference, using the reference line
method. Antibody levels were expressed in EU/ml.
The assay cut-offs were set at 5 EU/ml. The
between-day coefﬁcient of variation was 525% for
each assay. Antibody values were subsequently log-
transformed to establish geometric mean titers
(GMT) for further analyses.
Data were analyzed using SPSS 11.0 for Windows
(SPSS, Chicago, IL, USA). Student’s t-test, Mann–
Whitney U test, Pearson correlations and Pearson
chi square were used for statistical comparisons as
deemed appropriate.
Results
Mean (SD) maternal age, gestational age and birth
weight were 26.8 (6.8) years, 38.9 (1.4) weeks and
3239 (501) g, respectively. Detectable maternal
levels of anti-PT, FHA and PRN were found in
34.7%, 95.0% and 80.2% of samples, respectively.
Detectable cord blood levels of anti-PT, FHA and
PRN were seen in 44.6%, 93.2%, and 80.6% of
samples, respectively. Maternal and cord blood
geometric mean titers for anti-PT, FHA and PRN
are shown in Table I. There was no signiﬁcant
relationship between anti-PT, FHA or PRN detec-
tion or geometric mean titer and maternal age.
Maternal anti-PT, FHA, and PRN were signiﬁcantly
correlated (p50.001) with neonatal cord blood
values; r=0.98, 0.90 and 0.96, respectively.
Discussion
Pertussis is a highly communicable, vaccine-preven-
table respiratory disease caused by the organism
Bordetella pertussis. In the USA, the incidence of
reported cases has dramatically increased over the
last 10 years [1]. The highest incidence of new
pertussis cases is among infants (Table II). However,
the most rapidly increasing incidence has been noted
among adolescents and young adults [1,2]. The
epidemiology of pertussis in this latter population is
not well deﬁned, and clinicians commonly overlook
this diagnosis in otherwise healthy patients present-
ing with chronic cough [3]. A key concern is that
adult hosts act as a reservoir for the organism,
allowing for infection of pre-vaccinated, susceptible
newborns and young children, in whom morbidity
and mortality are more pronounced [4].
Despite the general perception that either natural
or vaccine-induced pertussis immunity is long lasting
and therefore protective, recent studies have demon-
strated adult susceptibility even in highly vaccinated
communities [5]. Serological surveillance data like-
wise highlight waning immunity as adolescence
approaches [1]. The data presented in our study,
speciﬁcally examining seroprevalence of Bordetella
pertussis antibodies in an obstetric and newborn
population, add support to these concerns regarding
adult susceptibility, and are in general agreement
with recently reported observations [6,7]. Even with
efﬁcient transplacental passage of passive immunity
to the newborn, our results also underscore the
possible lack of protection available to the newborn
immediately after delivery.
The antibodies studied in this investigation are
commonly examined in relation to Bordetella pertussis
infection and vaccine efﬁcacy [7,8]. However, a clear
understanding of the exact mechanisms underlying
immunity to pertussis is lacking. It is likely that
immunity to pertussis involves multiple humoral and
cellular responses that are not directed against a
single protective antigen. Anti-PT has been corre-
Table I. Geometric mean (SD) values for pertussis antibodies.
Antibody Maternal (n=101) Cord blood (n=103)
PT 4.4 (2.6) 5.6 (3.0)
PRN 12.3 (2.9) 10.2 (3.2)
FHA 26.6 (3.1) 32.0 (3.2)
Table II. Average annual incidence rates of pertussis in the USA,
1997–2000 [1].
Age (years) Cases (per 100,000)
51 55.5
1–4 5.5
5–9 3.6
10–19 5.5
520 0.8
60 B. Gonik et al.lated with clinical protection against Bordetella
pertussis infection in humans, but an absolute cut-
off value for protection has not been determined [5].
Similarly, the presence of anti-PRN correlates
crudely with clinical immunity against disease [5].
These two antibodies seem to be speciﬁc for
Bordetella pertussis, with no cross-reactivity to other
species [5]. Conversely, anti-FHA has been shown to
cross-react with Bordetella parapertussis, and therefore
the signiﬁcance of this antibody remains to be fully
elucidated [5].
The parturients and neonates in our study with
antibodies below detectable levels probably repre-
sented susceptible individuals. For anti-PT, this
comprised almost two thirds of the maternal samples
and almost one half of the newborn cord blood
specimens. Applying one reported set of criteria for
anti-PT and PRN cut-off levels for serologic
evidence of protection, the overwhelming majority
of our serologically positive subjects would also be
deemed moderately to highly susceptible to infection
[9].
Despite the controversy regarding absolute anti-
body values and host protection, our data, in
combination with recent epidemiologic studies re-
porting signiﬁcant rises in clinical pertussis cases,
should stimulate additional research in this area
[1,2,10]. Many authorities have already argued that
routine adolescent and adult re-vaccination with an
acellular pertussis agent should be considered, to
decrease disease burden and to control transmission
to susceptible newborn infants [11,12]. At a mini-
mum, healthcare providers and their clients should
be aware of the risk for infant infection via family
member transmission. This should lead to more
careful evaluation and testing of household contacts
with atypical coughs, with more attention to the use
of efﬁcacious antimicrobial therapies and prophylaxis
where indicated.
Acknowledgment
We would like to acknowledge our gratitude to
Dominique Descamps, Emmanuel Dael and the
Glaxo SmithKline Biologicals Laboratory in Rixen-
sart, Belgium, for their assistance in running the
antibody assays.
References
1. Centers for Disease Control and Prevention. Pertussis – USA,
1997–2000. MMWR recomm Rep 2002;51(4):73–76.
2. Yih WK, Lett SM, des Vignes FN, et al. The increasing
incidence of pertussis in Massachusetts adolescents and
adults, 1989–1998. J Infect Dis 2000;182:1409–1416.
3. Wright SW. Pertussis infection in adults. South Med J
1998;91:702–708.
4. Centers for Disease Control and Prevention. Guidelines for
the control of pertussis outbreaks. Atlanta, GA, USA: Centers
for Disease Control and Prevention; 2000.
5. Van de Wielen M, Van Damme P, Van Herck K, et al.
Seroprevalence of Bordetella pertussis antibodies in Flanders
(Belgium). Vaccine 2003;21:2412–2417.
6. Healy CM, Munoz FM, Rench MA, et al. Prevalence of
pertussis antibodies in maternal delivery, cord, and infant
serum. J Infect Dis 2004;190:335–340.
7. Belloni C, DeSilvestri A, Tinelli C, et al. Immunogenicity of a
three-component acellular pertussis vaccine administered at
birth. Pediatrics 2003;111:1042–1045.
8. Storsaeter J, Hallender HO, Gustafsson L, Olin P. Levels of
anti-pertussin antibodies related to protection after household
exposure to Bordetella pertussis. Vaccine 1998;16:1907–1916.
9. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for
serologic correlates of immunity to Bordetella pertussis cough
illnesses. Vaccine 1998;16:1901–1906.
10. Guris D, Strebel PM, Bardenheier B, et al. Changing
epidemiology of pertussis in the USA: increasing reported
incidence among adolescents and adults, 1990–1996. Clin
Infect Dis 1999;28:1230–1237.
11. Edwards KM. Pertussis: an important target for maternal
immunization. Vaccine 2003;21:3483–3486.
12. Health Canada. National consensus conference on pertussis.
Canada Communicable Disease Report 2001;2953:1–33.
Bordetella pertussis antibodies in mothers and newborns 61